ImmunityBio Faces Securities Fraud Lawsuit After FDA Warning, 21% Stock Plunge

ImmunityBio, Inc. has become the target of a securities fraud class action lawsuit following a damaging regulatory enforcement action by the U.S. Food and Drug Administration (FDA) that exposed allegedly misleading promotional materials for its cancer immunotherapy Anktiva. The FDA's warning letter, issued on March 24, 2026, triggered a sharp market correction, with the company's stock plummeting 21% to close at $7.42 per share—a significant decline that has prompted investor litigation against the biotech company's leadership.

The FDA Warning and Misleading Marketing Claims

The regulatory agency's warning letter represents a formal enforcement action against ImmunityBio for misrepresenting the efficacy and therapeutic potential of its flagship cancer therapy. According to the FDA's findings, the company's advertisements for Anktiva overstated the drug's ability to cure and prevent cancer, crossing the line from permissible promotional claims into false and misleading statements.

Key details of the regulatory enforcement action include:

• FDA issued warning letter on March 24, 2026
• Primary violation: Misrepresented Anktiva's curative and preventive capabilities
• Nature of misconduct: Advertisement and promotional materials contained unsubstantiated claims
• Company involved: ImmunityBio, Inc., a clinical-stage immunotherapy developer

FDA warning letters serve as formal notice that a company is in violation of federal pharmaceutical advertising regulations, particularly 21 CFR Part 202 and 21 CFR Part 312, which govern prescription drug promotion and investigational new drug applications. The issuance of such a letter typically signals serious compliance failures and creates immediate legal exposure for both the company and its executives.

Market Reaction and Class Action Litigation

The FDA's enforcement action triggered an immediate and substantial stock market reaction. Within days of the March 24 disclosure, ImmunityBio's share price collapsed 21%, falling from approximately $9.40 to $7.42 per share. This market correction wiped out billions in investor value and created a concrete basis for shareholder litigation.

Following this decline, class action lawyers at Kahn Swick & Foti, LLC, a securities litigation firm specializing in investor claims, initiated formal litigation on behalf of affected shareholders. The lawsuit targets investors who purchased ImmunityBio shares during a specific window period:

• Alleged class period: January 19, 2026 through March 24, 2026
• Stock decline: 21% (from ~$9.40 to $7.42)
• Lead plaintiff application deadline: May 26, 2026
• Lead counsel: Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

The class action mechanism allows individual investors who suffered losses during the specified period to consolidate their claims and pursue recovery from the company and potentially its officers and directors. The underlying legal theory typically alleges that company insiders knew or recklessly disregarded the fact that Anktiva's marketing claims were false and misleading, and that they failed to disclose this information to investors, thereby artificially inflating the stock price.

Market Context: Biotech Regulation and Investor Scrutiny

The ImmunityBio enforcement action reflects broader regulatory pressure on the biotechnology industry to ensure that promotional claims for investigational and newly approved therapies remain scientifically grounded and compliant with FDA standards. The agency has increasingly scrutinized cancer therapy marketing, particularly for immunotherapies, where patient populations are vulnerable and therapeutic claims may be subject to premature or exaggerated promotion.

Key market context factors include:

• Regulatory environment: FDA actively enforces advertising compliance through warning letters and enforcement actions
• Investor sensitivity: Biotech stock prices are highly sensitive to regulatory setbacks and clinical trial disappointments
• Fraud litigation landscape: Securities class actions in the biotech sector have increased as investors become more litigious
• Competitive pressure: ImmunityBio operates in the crowded oncology immunotherapy space, where Merck ($MRK), Bristol Myers Squibb ($BMY), Roche ($RHHBY), and others dominate

For a clinical-stage immunotherapy company like ImmunityBio, regulatory compliance failures represent existential threats. Any perception that the company has misled investors or regulators about Anktiva's therapeutic potential raises fundamental questions about management integrity and clinical data reliability. The FDA warning letter serves as a powerful indictment of the company's regulatory discipline.

Investor Implications and Path Forward

The securities fraud lawsuit carries several important implications for ImmunityBio shareholders, prospective investors, and the broader biotech market:

For current shareholders: The litigation introduces additional downside risk. Even if ImmunityBio ultimately prevails in defending against fraud allegations, legal defense costs, potential settlements, and reputational damage will strain resources and divert management attention from core research and development activities.

For prospective investors: The enforcement action and litigation should prompt careful due diligence regarding management credibility and regulatory compliance track records. The combination of an FDA warning letter and securities fraud allegations signals elevated governance risk.

For the biotech sector broadly: The ImmunityBio case reinforces the critical importance of maintaining rigorous standards around clinical trial reporting, data transparency, and promotional claim substantiation. Other companies should view this as a cautionary tale.

Investors who purchased ImmunityBio shares between January 19 and March 24, 2026—the period during which the company allegedly made misleading statements—have until May 26, 2026 to file lead plaintiff applications. Those interested in pursuing claims can contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC to discuss potential recovery options.

The lawsuit may ultimately result in a settlement, judgment, or dismissal. Settlements in biotech securities fraud cases typically range from 5-25% of investor losses, depending on litigation strength and insurance coverage. ImmunityBio will likely carry directors and officers liability insurance that could cover portions of any settlement, though coverage exclusions for fraud claims may apply.

Conclusion

The combination of FDA regulatory enforcement and shareholder litigation represents a severe blow to ImmunityBio's credibility, financial position, and near-term prospects. The 21% stock decline reflects market recognition that the company's promotional practices crossed ethical and legal boundaries, creating both immediate losses for shareholders and longer-term uncertainty about management's commitment to compliance and transparency. For investors holding ImmunityBio shares during the January-March 2026 period, the May 26 lead plaintiff deadline represents an important opportunity to formally document claims in the class action litigation. More broadly, the case underscores the securities law risks that biotech companies face when regulatory compliance, marketing practices, and investor communications fail to meet exacting legal and ethical standards.